Hester Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hester Biosciences has submitted copies of newspaper clippings (Financial Express, English and Gujarati, Ahmedabad edition, 2 August 2025) containing the extract of its unaudited consolidated financial results for Q1 FY26, in compliance with SEBI listing rules. Consolidated total income rose modestly to INR 864.21 million from INR 834.92 million in Q1 FY25, while net profit after tax jumped sharply to INR 172.96 million from INR 74.86 million, a YoY increase of about 131%. Sequentially, PAT recovered strongly from a weak Q4 FY25 figure of INR 15.41 million. Consolidated EPS for the quarter stood at INR 20.33 versus INR 8.80 a year ago. Standalone results were also disclosed, with standalone PAT at INR 78.38 million (Q1 FY26) versus INR 84.32 million (Q1 FY25).
This is a routine regulatory filing (newspaper publication of results already filed with the exchanges), so the market impact is limited. However, the strong YoY growth in consolidated profit and EPS is a positive signal for shareholders, though the modest top-line growth suggests the profit jump was largely margin or cost driven rather than a broad revenue acceleration.